

Shuwen Biotech Announces Inclusion of Proprietary Biomarker of Preeclampsia into Clinical Practice Consensus

Shuwen Biotech Announces Inclusion of Proprietary Biomarker of Preeclampsia into Clinical Practice Consensus

DEQING, CHINA, March 10, 2021 /EINPresswire.com/ -- Shuwen Biotech, a China-based



We are happy that key opinion leaders have recognized the value of our product in preeclampsia prevention and management."

Jay Z. Zhang, Chairman and CEO of Shuwen Biotech

integrated in vitro diagnostics company, today announced that its proprietary biomarker for preeclampsia, urine misfolded proteins, has been recognized as a valuable diagnostic marker for preeclampsia and included in a clinical physician practice consensus of the Henan Province in China. The "Expert Consensus for Preeclampsia Prevention and Treatment" recommends testing of urine misfolded proteins to screen for risk of preeclampsia among women in weeks 14 to 19+6, and after week 20, of pregnancy.

Shuwen's Preeclampsia Detection Kit, the world's first commercial urine-based point-of-care diagnostic device, was developed for the detection of urine misfolded proteins in pregnant women, and has been approved and marketed in China and many other countries.

"We are happy that key opinion leaders have recognized the value of our product in preeclampsia prevention and management. We will work hard with partners around the world to get the product in the hands of physicians and pregnant women to improve the quality of pregnancy and save lives," said Jay Z. Zhang, Chairman and CEO of Shuwen Biotech.

About Shuwen Biotech

Shuwen Biotech is a China-based diagnostic company founded on the principles of innovation, patent protection, and international collaboration as its strategic platforms for growth. Since 2011, Shuwen established strategic partnerships with numerous outstanding academic and commercial institutions to commercialize first-in-class diagnostic technologies and patents and has developed a range of novel diagnostics in the fields of cancer and women's health. Shuwen has also developed quality companion diagnostics and provided central lab biomarker testing services to leading pharmaceutical developers. Shuwen houses an in-house development team,

CAP-accredited central labs, and ISO13485-certified IVD manufacturing facilities, all in line with global standards to continue to deliver transformational products and services to its customers globally and open new possibilities in the advancement of health.

Vafa Amirikia, Ph.D.

Shuwen Biotech

+86 572 889 9881

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/536608317>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.